您好,欢迎访问中山大学肿瘤防治中心官方网站!
内部网 职工邮箱 图书馆 OA系统 医生门户 English
院士风采 首席专家 临床专家 科研学者 客座教授 人才名录
首页
  • 文石军

    职务:中山大学“百人计划”引进人才
    职称:博士、副研究员,硕士生导师
    专长:肿瘤细胞代谢及其表观遗传相关酶进行抗肿瘤药物分子的设计与合成研究
    教育与研究经历
      吉林大学化学系化学专业本科毕业,中国科学院上海有机化学研究所生命有机化学国家重点实验室有机化学博士毕业。2005年至2010年曾在英国南安普敦大学和剑桥大学进行博士后学习,分别从事组蛋白去乙酰酶抑制剂和结核病菌泛酸合成酶抑制剂的研究。2010年11月入选中山大学“百人计划”引进人才,从事新颖抗肿瘤药物的研究。主要研究成果为完成抗炎环肽天然产物cyclomarin C的首例全合成,完成天然产物组蛋白去乙酰抑制剂azumamide A,E和FK228(亦即临床抗癌药)的全合成,在J. Org. Chem.,Org. Lett.,J. Med. Chem.,Chem. Biol.,Angew. Chem. Int. Ed.等杂志上发表SCI论文20多篇,申请中国发明专利3项,国际PCT专利1项。

    主要研究方向
      针对肿瘤细胞代谢及其表观遗传相关酶进行抗肿瘤药物分子的设计与合成研究,以及探索新颖化学合成方法构建具有生物活性的药物分子骨架。

    近年基金资助
      1. 中山大学“百人计划”引进人才启动基金(负责)  
      2. 教育部博士点基金 (负责)
      3. 广东省科技化对外合作基金(负责)
      4. 国家自然科学基金重点项目(主要参与)

    联系方式
    E-mail: wenshj@sysucc.org.cn
     

    联系方式
    E-mail:
    wenshj@sysucc.org.cn


    教育与研究经历
      吉林大学化学系化学专业本科毕业,中国科学院上海有机化学研究所生命有机化学国家重点实验室有机化学博士毕业。2005年至2010年曾在英国南安普敦大学和剑桥大学进行博士后学习,分别从事组蛋白去乙酰酶抑制剂和结核病菌泛酸合成酶抑制剂的研究。2010年11月入选中山大学“百人计划”引进人才,从事新颖抗肿瘤药物的研究。主要研究成果为完成抗炎环肽天然产物cyclomarin C的首例全合成,完成天然产物组蛋白去乙酰抑制剂azumamide A,E和FK228(亦即临床抗癌药)的全合成,在J. Org. Chem.,Org. Lett.,J. Med. Chem.,Chem. Biol.,Angew. Chem. Int. Ed.等杂志上发表SCI论文20多篇,申请中国发明专利3项,国际PCT专利1项。

    主要研究方向
      针对肿瘤细胞代谢及其表观遗传相关酶进行抗肿瘤药物分子的设计与合成研究,以及探索新颖化学合成方法构建具有生物活性的药物分子骨架。

    近年基金资助
      1. 中山大学“百人计划”引进人才启动基金(负责) 
      2. 教育部博士点基金 (负责)
      3. 广东省科技化对外合作基金(负责)
      4. 国家自然科学基金重点项目(主要参与)

    主要论著:
      1. Liu Z., Zhu D, Luo B, Zhang N, Liu Q, Hu Y, Huang P, Wen S*. Mild Cu(I)-catalyzed cascade reaction of cyclic diaryliodoniums, sodium azide and alkynes: efficient synthesis of triazolophenanthridines Organic Letters 2014, accepted, DOI: 10.1021/ol502654a.(IF 6.32)
      2. Wu Y, Peng X, Luo B, Wu F-H, Liu B, Song F-Y, Huang P, Wen S*. Palladium catalyzed dual C-H functionalization of indoles with cyclic diaryliodoniums, an approach to ring fused carbazole derivatives Org. Biomol. Chem. 2014, accepted, DOI: 10.1039/C4OB02170C. (IF 3.49)
      3. Zhu D, Wu Y, Wu B, Luo B, Ganesan A, Pi R, Wu F-H, Huang P, Wen S*. Three-component Pd/Cu-catalyzed cascade reactions of cyclic iodoniums, alkynes, and boronic acids: an approach to methylidenefluorenes. Organic Letters 2014, 16, 2350-2353. (IF 6.32)
      4. Li M, Luo B, Liu Q, Hu Y, Ganesan A, Huang P, Wen S*. Synthesis of N-acyl-N,O-acetals Mediated by Titanium Ethoxide. Org. Lett. 2014, 16, 10-13. (IF 6.32)
      5. Chen M, Liu Q, Liu A, Tan M, Xie Z, Uri A, Chen Z, Huang G, Sun Y, Ge H, Liu P, Li M, Li X, Wen S*, Pi R* Simply combining fasudil and lipoic acid in a novel multitargeted chemical entity potentially useful in central nervous system disorders. RSC Advances, 2014, 37266-37269. (IF 3.7)
      6. Mageed SN, Cunningham F, Hung AW, Silvestre HL, Wen S, Blundell TL, Abell C, McConkey GA. Pantothenic acid biosynthesis in the parasite Toxoplasma gondii: a target for chemotherapy. Antimicrob Agents Chemother. 2014 Jul 21. pii: AAC.02640-14. [Epub ahead of print] (IF 4.45)
      7. Chen M, Tan M, Jing M, Liu A, Liu Q, Wen S, Chen Z, Chao X, He X, Ramassamy C, Gao Y, Pi R. Berberine protects homocysteic acid-induced HT-22 cell death: involvement of Akt pathway. Metab Brain Dis. 2014 Jul 23. [Epub ahead of print] (IF 2.40)
      8. Wang L, Wang R, Jin M, Huang Y, Liu A, Qin J, Chen M, Wen S, Pi R, Shen W. Carvedilol Attenuates 6-Hydroxydopamine-Induced Cell Death in PC12 Cells: Involvement of Akt and Nrf2/ARE Pathways. Neurochem Res. 2014 Jun 21. [Epub ahead of print] (IF 2.55)
      9. Wen, S., Zhu, D., Huang, P. Targeting Cancer Cell Mitochondria as a Therapeutic Approach, Future Med. Chem. 2013, 5(1):53-67. (IF 4.0)
      10. Zhu D, Liu Q, Luo B, Chen M, Pi R, Huang P, Wen S*. Synthesis of Carbazoles via One-Pot Copper-Catalyzed Amine Insertion into Cyclic Diphenyleneiodoniums as a Strategy to Generate a Drug-Like Chemical Library. Adv. Synth. Catal. 2013, 355, 2172-2178 (IF 5.54)
      11. Zhu D, Chen M, Li M, Luo B, Zhao Y, Huang P, Xue F, Rapposelli A, Pi R, Wen S*. Discovery of novel N-substituted carbazoles as neuroprotective agents with potent anti-oxidative activity. Eur. J. Med. Chem. 2013, 68, 81-88. (IF 3.50)
      12. Guan R, Xu X, Chen M, Hu H, Ge H, Wen S*, Zhou S, Pi R. Advances in the studies of roles of Rho/Rho-kinase in diseases and the development of its inhibitors. Eur. J. Med. Chem. 2013, 70, 613-622. (IF 3.50)
      13. Zhou B, Zuo Y, Li B, Wang H, Liu H, Wang X, Qiu X, Hu Y, Wen S, Du J, Bu X. Deubiquitinase Inhibition of 19S Regulatory Particles by 4-Arylidene Curcumin Analogue AC17 Causes NF-κB Inhibition and p53 Reactivation in Human Lung Cancer Cells. Mol Cancer Ther. 2013, 12(8):1381-92. (IF 5.23)
      14. Li X, Lu W, Hu Y, Wen S, Qian C, Wu W, Huang P. Effective inhibition of nasopharyngeal carcinoma in vitro and in vivo by targeting glycolysis with oxamate. Int. J. Oncol. 2013, 43(5): 1710-1718. (IF 2.40)
      15. Abrahams GL, Kumar A, Savvi S, Hung AW, Wen S, Abell C, Barry CE 3rd, Sherman DR, Boshoff HI, Mizrahi V. Pathway-Selective Sensitization of Mycobacterium tuberculosis for Target-Based Whole-Cell Screening. Chem Biol. 2012, 27, 19(7), 844-54. (IF 6.59)
      16. Tiffon C., Adams J., van der Fits L., Wen S, Townsend P., Ganesan A., Hodges E., Vermeer M., Packham G. The histone deacetylase inhibitors Vorinostat and Istodax downmodulate IL10 expression in cutaneous T-cell lymphoma cells British Journal of Pharmacology 2011, 162,1590-1602. (IF 4.99)
      17. Hung A.W., Silvestre H.L., Wen S, Ciulli A., Blundell T.L., Abell C. Application of fragment growing and fragment linking to the discovery of novel inhibitors of Mycobacterium tuberculosis pantothenate synthetase Angew. Chem. Int. Ed. 2009, 48, 8452-8456. (IF11.34)
      18. Heikkila T.J., Surade S., Silvestre H.L., Dias M.V.B., Ciulli A., Bromfield K., Scott D., Howard N., Wen S, Wei A.H., Osborne D., Abell C. Blundell T.L. Fragment-based drug discovery in academia: experiences from a tuberculosis programme NATO Security through Science Series C: Environmental Security, 2009, 21-36.
      19. Wen S, Packham, G., Ganesan, A. Macrolactamization versus Macrolactonization: Total Synthesis of FK228, the Depsipeptide Histone Deacetylase Inhibitor J Org Chem, 2008, 73, 9353-9361. (IF 4.64)
      20. Wen S, Carey K., Nakao Y., Fusetani N., Packham G., Ganesan A. Total Synthesis of Azumamide A and Azumamide E, Evaluation as Histone Deactylase Inhibitors, and Design of a More Potent Analogue Organic Letters 2007, 9 (6), 1105-1108. (IF6.32)
      21. Yurek-George A., Cecil A., Mo A.H.K., Wen S, Rogers H., Maeda S., Yoshida M., Packham G., Ganesan A., The First Biologically Active Synthetic Analogues of FK228, the Depsipeptide Histone Deacetylase Inhibitor, J. Med. Chem. 2007; 50(23); 5720-5726. (IF5.48)
      22. Wen, SJ, Hu, T.-S., Yao, Z.-J. Macrocylization Studies and Total Synthesis of Cyclomarin C, an Anti-inflammatory Marine Cyclopeptide, Tetrahedron 2005, 61 (21), 4931-4938. (IF2.82)
      23. Wen, SJ, Yao, Z.-J. Total Synthesis of Cyclomarin C. Organic Letters 2004, 6 (16) 2721-2724. (IF6.32)

    专利申请:
      1. 文石军,黄蓬:还原型烟酰胺腺嘌呤二核苷酸氧化酶抑制剂芳香碘鎓盐及其抗肿瘤应用(专利申请号201210057259.6)。
      2. 文石军,黄蓬,朱大潜,黎小兵:一种二苯并碘鎓盐及其抗癌应用(专利申请号201310070771.3)。
      3. 黄蓬,文石军,罗冰玲:一种异硫氰酸酯及其制备方法与抗癌应用(专利申请号201310096751.3)。

                         更新时间:2014.10.23

访客通道
员工通道
关注肿瘤医院